Join Rakovina Therapeutics and Variational AI for a 60-minute fireside chat on how deep biology and generative AI are coming together to tackle one of oncology’s toughest problems: designing CNS-penetrant, multi-target cancer therapies. Using their ATR/mTOR inhibitor collaboration as a case study, the teams will walk through how they met, the biological challenge they were trying to solve, how Variational’s Enki™ platform generated brain-penetrant candidates, and what the latest preclinical data mean for patients, partners, and shareholders.
The first ~35 minutes will be a conversational discussion between Rakovina and Variational AI—no slides, just the real story behind the science and the partnership—followed by ~25 minutes of open, town-hall style Q&A where you can ask questions live or via chat.
Attend to hear validated results from a cutting-edge AI–drug discovery collaboration, understand where the program is headed next, and engage directly with the people driving this Canadian innovation.
- Date: December 17, 2025
- Time: 10:00 AM PST
- Total Duration: 60 Minutes
- Structure: 35 Minutes (Discussion) / 25 Minutes (Open Q&A)
- Anchor: Jeffrey Bacha, Chairman, Rakovina Therapeutics Inc
- Speakers:
- Mads Daugaard, Co-Founder, President & CSO, Rakovina Therapeutics Inc
- Handol Kim, Co-Founder & CEO, Variational AI
Cannot attend? You can still register; the recording will be sent to you after the event